About
Welcome to the Solutions for Celiac website.
This NIH-funded clinical research study has been designed to assess the drink-based study medication latiglutenase and, in conjunction with a gluten-free diet, its ability to relieve common symptoms suffered by celiac disease patients typically experienced after accidental gluten exposure.
What to Expect
Study Medication
Latiglutenase is a combination of two enzymes that target and degrade gluten proteins in the stomach, rendering them inactive and less likely to cause the symptoms and intestinal damage associated with celiac disease.
The study medication is provided in powder form that, when mixed with a flavor packet in water, produces a clear liquid to be consumed with a meal.
Participation
-
Make 6 clinic visits over approximately 26 weeks
-
Report your daily celiac disease symptoms online
-
Complete study-related medical assessments
-
Maintain your gluten-free diet
-
Less than 5 times a month, eat a study-provided snack that is either gluten-free or gluten-containing (to simulate accidental gluten exposure)
-
Study medication and study-related tests and procedures at no cost to you
-
Transportation and parking reimbursement may be provided
Contribution
Your voluntary participation contributes data that is anonymous and confidential.
After the study is completed, data from all participants will be analyzed by the study team to determine if the study medication improves symptoms of accidental gluten exposure compared to placebo.
